RxDoctor Payments DataLook up a doctor →

Oliver Achi, MD

Neurology · Lafayette, LANPI 1841684263

Payments from drug & device makers

$187,049in general payments, 2019–2025

Across 359 payments — averaging $521.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$133K
  • Argenx US, Inc.$45K
  • Vertex$3K
  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$505
  • UCB, Inc.$391
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,35697%
  • Education$2063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$187,049 in reported general payments places this provider in the 90th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$188,130
Medicare patients
326
Services billed
18,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4651$335,978
UbrelvyUbrogepant54$76,865
BotoxOnabotulinumtoxina37$68,315
Aimovig AutoinjectorErenumab-Aooe78$58,253
QuliptaAtogepant35$46,972
XcopriCenobamate28$40,657
Emgality PenGalcanezumab-Gnlm40$39,306
RytaryCarbidopa/Levodopa38$38,071
Nurtec OdtRimegepant Sulfate22$24,075
RexultiBrexpiprazole13$19,061
NamzaricMemantine Hcl/Donepezil Hcl27$18,701
FycompaPerampanel13$18,094
NuedextaDextromethorphan Hbr/Quinidine11$17,406
TrileptalOxcarbazepine13$14,102
EliquisApixaban16$9,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta, Namzaric$2,119$210,853153 claims
SK Life Science, Inc.Xcopri$173$40,65728 claims
Amneal Pharmaceuticals LLCRytary$103$38,07138 claims
PfizerNurtec Odt, Eliquis$270$33,42938 claims
Otsuka America Pharmaceutical, Inc.Rexulti$166$19,06113 claims
Eisai Inc.Fycompa$217$18,09413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 225 neurology providers in Louisiana.

Other neurology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →